PPD will take Belgian firm's drugs through Phase II
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
WILMINGTON, N.C. — PPD Inc. (Nasdaq: PPDI) said Tuesday that it has signed a deal with Belgian drug-maker Janssen Pharmaceutica N.V. to take two developmental compounds through Phase II trials and possibly to market.
The Belgian company, part of Johnson & Johnson, has been working on the drugs to treat, respectively, diarrhea-predominant irritable bowel syndrome (IBS-d) and complicated skin and skin structure and respiratory infections.
Under two agreements, PPD has in-licensed the two compounds and will advance them through Phase II development, PPD said. After that, Janssen can resume development and commercialization and pay PPD up to $330 million in clinical and sales milestones and royalties if the drugs go to market.
Alternatively, PPD can continue developing and commercializing either compound if Janssen does not buy it back. If PPD gets both drugs, it will pay Janssen up to $250 million in clinical and sales milestones and royalties on sales, the company said in an announcement.
Copyright 2010 Local Tech Wire. All rights reserved.Featured
Hot Off The Wire
- Hot Off the Wire – Google slashes Nexus One termination fee; MySpace Music tunes up audio ads; Barry Diller’s IAC beats Street
- Hot Off the Wire – Man convicted in first economic espionage case; iPhone market share grows; Electronic Arts shares falter after revenue forecast; Phone company wants to charge Google
- FairPoint looks to cut debt by two thirds with bankruptcy plan
E-mail Preferences
The Skinny
- Gears of War 3 coming? EA discloses Epic game for 2011
- Nagoya University bridges East, West with Nu Tech event
- E-mail services provider iContact investigating a hack attack
- Cyberespionage? Cyberslueths disclose Lenovo’s 2010 ‘roadmap’
- Tech recovery is at hand, analysts tells N.C. IT execs
- Believe it - Triangle region lands record $1.9B in business projects
- Epic Games’ heroes take their guns to a new world – ‘Lost Planet 2’
- IPO rewards: Motricity CEO gets a $75,000 raise in new contract
- IT recession over? Spending will rebound, analysis firm says
- Google vs. the Dragon – War over words could ignite into flames

